FDA Advisors Back Eli Lilly's Donanemab for Alzheimer's Treatment
Monday, 10 June 2024, 19:56
FDA Advisors' Endorsement of Donanemab
If approved, Eli Lilly's donanemab would be the latest entrant in the Alzheimer's drug landscape after Biogen's Leqembi, showcasing growing emphasis on addressing this challenging health issue.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.